Inhibition of angiogenesis in the anterior chamber of the eye;Antiangiogene Therapie am Vorderen Augenabschnitt

Ophthalmologe

Volumn 104, Issue 4, 2007, Pages 336-344

  Bock, F ^a   Konig Y ^a   Dietrich, T ^a   Zimmermann, P ^a   Baier, M ^b   Cursiefen, C ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Angiogenesis; Conjunctiva; Cornea; Inhibition of angiogenesis; VEGF

Indexed keywords

EID: 34247494627     PISSN: 0941293X     EISSN: 14330423     Source Type: Journal    
DOI: 10.1007/s00347-007-1512-2     Document Type: Article

References (36)

1. Bock F, Onderka J, Dietrich T et al. (2007)Bevacizumab is a potent inhibitor of inflammatory an giogenesis and lymphangiogenesis in the cornea. Invest Ophthalmol Vis Sci (im Druck)
2. Chen L, Hamrah P, Cursiefen C et al. (2004) Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) mediates dendritic cell migration to lymph nodes and induction of immunity to corneal transplants. Nature Medicine 10: 813-815
3. Cursiefen C (2007) Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy. 92: 50-57
4. Cursiefen C, Schlötaer-Schrehardt U, Küchle M et al. (2002) Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and Podoplanin. Invest Ophthalmol Vis Sci 43: 2127-2135
5. Cursiefen C, Chen L, Dana MR et al. (2003) Corneal lymphangiogenesis: Evidence, mechanisms and implications for transplant immunology. Cornea 22: 273-2781
6. Cursiefen C, Seitz B, Dana MR et al. (2003) Angiogenese und Lymphangiogenese in der Hornhaut Pathogenese, Klinik und Therapieoptionen. Ophthalmologe 100: 292-299
7. Cursiefen C, Rummelt C, Neuhuber W, et al. (2006) Absence of blood and lymphatic vessels in the developing human cornea. Cornea 25: 722-726
8. Cursiefen C, Maruyama K, Liu Y et al. (2004) Inhibition of hem- and lymphangiogenesis after normalrisk corneal transplantation by neutralizing VEGF promotes graft survival Invest Ophthalmol Vis Sci 45: 2666-2673
9. Cursiefen C, Chen L, Saint Geniez M et al. (2006) Nonvascular VEGF receptor 3 expression by cor neal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 103: 11405-11410
10. Cursiefen C, Seitz B, Kruse F (2005) Hornhauttransplantarjon: Glänzende Bilanz und viele Perspektiven. Deutsches Ärztebl 102: A-3078
11. Cursiefen C, Chen L, Borges L, Jackson D, D'Amore PA, Dana MR, Wiegand SJ, Streilein JW. Via bone marrow-derived macrophages, VEGF A mediates lymph- and hemangiogenesis in inflammatory neovascularization. J Clin Investigation 111 1040-1050
12. Cursiefen C, Ikeda S, Nishina PM et al. (2005) Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3-signaling. Am J Pathol 166: 1367-1377
13. Cursiefen C, Masli S, Ng TF et al. (2004) Roles of thrombospondin 1 and 2 in regulating spontaneous and induced angiogenesis in the cornea and iris. Invest Ophthalmol Vis Sci 45: 1117-1124
14. Cursiefen C, Maruyama M, Jackson DG et al. (2006) Time-course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 25: 443-447
15. Cursiefen C, Martus P, Nguyen NX et al. (2002) Cor neal neovascularization after nonmechanical versus mechanical corneal trephination for non-high-risk keratoplasty. Cornea 21: 648-652
16. Cursiefen C, Wenkel H, Martus P et al (2001) Peripheral corneal neovascularization after non-high risk keratoplasty: influence of short- versus longtime topical steroids. Graefe's Arch Clin Exp Ophthalmol 239: 514-521.
17. Cursiefen C, Wenkel H, Langenbucher A et al. (2001) Standardisiertes Beurteilungsschema zur semiquantitativen Analyse der kornealen Neovaskularisation mittels projizierter Homhautphotographien. Klin Monatsbl Augenheilkd 218:484-491
18. Cursiefen C, Rummelt C, Küchle M (2000) Immunohistochemical localization of VEGF, TGFa and TGFb 1 in human corneas with neovascularization. Cornea 19: 526-533
19. Cursiefen C, Rummelt C, Küchle M et al. (2003) Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 87: 101-106
20. Geitzenauer W, Michels S, Prager F et al. (2006) Ear lfy effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related ma cular degeneration. Klin Monatsbl Augenheilkd 223: 822-827
21. Grisanti S, Biester S, Peters S et al. (2006) Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 142: 158-160
22. Iliev ME, Dornig D, Wolf Schnurrbursch U (2006) Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142: 1054-1056
23. Jonas JB, Spandau UH, Schlichtenbrede F (2007) Intravitreal Bevacizumab for filtering surgery. Ophthalmic Res 39:121-122
24. Kahook MY, Schumann JS, Noecker RJ (2006) Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging 37: 148-150
25. Klink T, Guthoff R, Grehn F (2006) Postoperative care after glaucoma filtration surgery. Ophthalmologe 103: 815-823
26. Kria L, Ohira A, AmemiyaT (1998) TNP-470 (a fungus-derived inhibitor of angiogenesis) reduces proliferation of cultured fibroblasts isolated from primary pterygia: a possible drug therapy for pterygia. Curr Eye Res 17: 986-993
27. Kuhlmann A, Amann K, Schlötzer Schrehardt U (2005) Endothelin-1 and Eta/Etb-receptor expression in normal & vascularized human cornea. Cornea 24: 837-844
28. Manzano R et al. (2007) Inhibition of experimental corneal neovascularization by Bevacizumab (AVASTIN). Br J Ophthalmol (in press)
29. Maruyama K, Li M, Cursiefen C et al. (2005) Inflammatory lymphangiogenesis arises from CD11 b+ cells. J Clin Invest 115: 2363-2372
30. Nguyen N, Seitz B, Langenbucher A et al. (2004) Clinical aspects and treatment of immune reactions following penetrating normal-risk keratoplasty. Klin Monatsbl Augenheilkd 221: 467-472
31. Pillai CT, Dua HS, Hossain P (2000) Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 41: 2148-2153
32. Shaunak S, Thomas S, Gianasi E et al. (2004) Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 22 977-984
33. Shojaei F, Fenara N (2007) Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest (Epub ahead of print)
34. Vinh L, Nguyen N, Martus P (2006) Surgery-related factors influencing corneal neovascularization after low-risk keratoplasty. Am J Ophthalmol 141: 260-266
35. Wong J, Wang N, Miller JW (1994) Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res 58: 439-451
36. Yeah J, Sims J, Guymer RH (2006) A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother 7: 2355-2368